New cancer clinical trial: A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Published on: January 29, 2018 at 12:00PM
Condition:   Ovarian Cancer
Intervention:   Drug: Prexasertib
Sponsor:   Eli Lilly and Company
Not yet recruiting
http://ift.tt/2nlvQdb